For the Inventor, By the Inventor

Enter assignee name

Edinburgh, United Kingdom

Nucana Plc

USPTO Granted Patents = 28

CIPO Patents = 30

EPO Patents = 21

Trademarks = 6

Forward Citations = 97

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Hugh Griffith (19 out of 19 patents)

Christopher McGuigan (12 out of 38 patents)

Gordon Kennovin (8 out of 8 patents)

4. Magdalena Slusarczyk (8 out of 11 patents)

5. Michaela Serpi (7 out of 8 patents)

6. Venkata Lakshmi Narasimha Rao Dammalapati (5 out of 12 patents)

7. Mani Bushan Kotala (5 out of 9 patents)

8. Valentina Ferrari (5 out of 5 patents)

9. Jan Balzarini (4 out of 33 patents)

10. Blanka Gonczy (4 out of 7 patents)

11. Paola Murziani (4 out of 7 patents)

12. Carmen Jimenez Antunez (3 out of 3 patents)

13. Fabrizio Pertusati (2 out of 4 patents)

14. Chris Pepper (1 out of 2 patents)

15. Chris McGuigan (1 out of 2 patents)

28 patents: Sort by Forward Citations

1. 12357652 - Formulations of phosphoramidate derivatives of nucleoside drugs (2025-07-15),

2. 12054511 - Synthesis of phosphate derivatives (2024-08-06),

3. 12054510 - 2' and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds (2024-08-06),

4. 11925658 - Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer (2024-03-12),

5. 11897913 - Synthesis of 3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)]phosphate (NUC-738) (2024-02-13),

6. 11786544 - Formulations of phosphoramidate derivatives of nucleoside drugs (2023-10-17),

7. 11707477 - Formulation comprising a gemcitabine-prodrug (2023-07-25),

8. 11629164 - Gemcitabine prodrugs (2023-04-18),

9. 11603382 - Diastereoselective synthesis of phosphate derivatives (2023-03-14),

10. 11560400 - Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds (2023-01-24),

11. 11559542 - Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer (2023-01-24),

12. 11414452 - Synthesis of phosphate derivatives (2022-08-16),

13. 11414451 - Floxuridine synthesis (2022-08-16),

14. 11400107 - Cancer treatments (2022-08-02),

15. 11377467 - Crystalline form of gemcitabine (2022-07-05),

NuCana is a clinical-stage biopharmaceutical company focused on transforming the treatment of cancer. They utilize their proprietary ProTide technology platform to develop and commercialize novel medicines that overcome key limitations of existing nucleotide analogs used in chemotherapy. Their innovative approach aims to enhance drug efficacy, reduce side effects, and improve outcomes for cancer patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

28 Patents

#9 in Edinburgh

#630 in United Kingdom

#22,535 in the World

Edinburgh, United Kingdom

Nucana Plc

Forward Citations = 97

32 inventors:

Hugh Griffith (19 out of 19 patents)

Christopher McGuigan (12 out of 38 patents)

Gordon Kennovin (8 out of 8 patents)

4. Magdalena Slusarczyk (8 out of 11 patents)

5. Michaela Serpi (7 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…